Clinical Trials Logo

Chlorhexidine clinical trials

View clinical trials related to Chlorhexidine.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06411522 Recruiting - Periodontitis Clinical Trials

Clinical and Microbiological Comparison of 0.2% CHX and 0.05% CHX+0.05%CPC Mouthwashes in TPS Patients

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The present study compares the effectiveness of two mouthwash formulations (0.2% CHX and 0.05% CHX+0.05%CPC) in reducing gingival inflammation and microbial colonization in individuals with gingivitis and in preventing periodontitis recurrence. The main focus is on assessing the clinical impact of the mouthwashes over six months, with a secondary goal of evaluating their effect on systemic blood pressure.

NCT ID: NCT05682833 Recruiting - Periodontitis Clinical Trials

Adjunctive Use Of A Novel Hyaluronic Acid/Chlorhexidine Gel In The Non Surgical Treatment Of Periodontitis

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

General Objective : To evaluate the outcome of non surgical periodontal therapy with local drug delivery adjunct to scaling and root planning Specific Objective : To determine the effect of intra-pocket application of hyaluronic acid /chlorohexidine gel in non surgical periodontal treatment on clinical periodontal parameters and microbiological level .

NCT ID: NCT05548361 Recruiting - Periodontitis Clinical Trials

The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study is determining the additional effect of a 2-week home usage of chlorhexidine in periodontitis patients undergoing scaling and root planing supplemented with a dual-strain probiotic lozenge.

NCT ID: NCT05142969 Recruiting - Surgery Clinical Trials

Chlorhexidine Bathing to Prevent Hospital-acquired Infections: the CLEANS Study

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Hospital-acquired infections (HAI) have been shown to increase length of hospital stay and mortality. Infections acquired during a hospital stay have been shown to be preventable. The skin of patients is considered a major reservoir for pathogens associated with hospital-acquired infections, and has been suggested as a potential target for interventions to reduce bacterial burden and subsequent risk of infection. The use of daily Chlorhexidine (CHG) bathing in intensive care patients has been advocated to reduce many of the infections in critically ill patients. However, the effectiveness of CHG bathing to reduce ICU infections has varied considerably among published trials, making the effectiveness of CHG bathing in ICU patients uncertain.

NCT ID: NCT04256798 Recruiting - Anesthesia Clinical Trials

Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery

PENGUIN
Start date: November 13, 2020
Phase: Phase 3
Study type: Interventional

PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery. Patients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.

NCT ID: NCT03442023 Recruiting - Clinical trials for Ventilator Associated Pneumonia

Different Oral Colonization of Gram-negative Bacteria in ICU Patients When Using Chlorhexidine at 0.12% Versus Chlorhexidine at 2.0%

Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

This study will assess the utility of different chlorhexidine mouthwash concentrations on ICU patients to decolonize their oral cavities from gram-negative bacteria, since this is a non-desirable condition that leads to higher mortality rates and longer hospitalization times. One group will receive the 0.12% chlorhexidine mouthwash and the other group will receive the 2% chlorhexidine mouthwash.